The Ischemic Cascade: Events Within the Penumbra

The Ischemic Penumbra

Volumn , Issue , 2007, Pages 59-76

  Klehmet, Juliane ^a   Dirnagl, Ulrich ^a   Dreier, Jens Peter ^a   Meisel, Andreas ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349916932     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420047356-9     Document Type: Chapter

References (193)

1. Ginsberg MD. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis lecture. Stroke 2003; 34(1):214-223.
2. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 1999; 22(9):391-397.
3. Nowicky AV, Duchen MR. Changes in [Ca2+]i and membrane currents during impaired mitochondrial metabolism in dissociated rat hippocampal neurons. J Physiol 1998; 507(1):131-145.
4. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4(5):399-415.
5. Lauritzen M, Hansen AJ. The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression. J Cereb Blood Flow Metab 1992; 12(2):223-229.
6. Muller M, Somjen GG. Na(+) dependence and the role of glutamate receptors and Na(+) channels in ion fluxes during hypoxia of rat hippocampal slices. J Neurophysiol 2000; 84(4):1869-1880.
7. Jarvis CR, Anderson TR, Andrew RD. Anoxic depolarization mediates acute damage independent of glutamate in neocortical brain slices. Cereb Cortex 2001; 11(3):249-259.
8. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischemia is mainly by reversed uptake. Nature 2000; 403(6767):316-321.
9. Nallet H, MacKenzie ET, Roussel S. The nature of penumbral depolarizations following focal cerebral ischemia in the rat. Brain Res 1999; 842(1):148-158.
10. Selman WR, Lust WD, Pundik S, et al. Compromised metabolic recovery following spontaneous spreading depression in the penumbra. Brain Res 2004; 999(2):167-174.
11. Shinohara M, Dollinger B, Brown G, et al. Cerebral glucose utilization: local changes during and after recovery from spreading cortical depression. Science 1979; 203(4376):188-190.
12. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory [Review]. Brain 1994; 117(Pt 1):199-210.
13. Leão AAP. Further observations on the spreading depression of activity in the cerebral cortex. J Neurophysiol 1947; 10:409-414.
14. Branston NM, Strong AJ, Symon L. Extracellular potassium activity, evoked potential and tissue blood flow. Relationships during progressive ischemia in baboon cerebral cortex. J Neurol Sci 1977; 32(3):305-321.
15. Aitken PG, Tombaugh GC, Turner DA, et al. Similar propagation of SD and hypoxic SD-like depolarization in rat hippocampus recorded optically and electrically. J Neurophysiol 1998; 80(3):1514-1521.
16. Strong AJ, Smith SE, Whittington DJ, et al. Factors influencing the frequency of fluorescence transients as markers of peri-infarct depolarizations in focal cerebral ischemia. Stroke 2000; 31(1):214-222.
17. Back T, Kohno K, Hossmann KA. Cortical negative DC deflections following middle cerebral artery occlusion and KCl-induced spreading depression: effect on blood flow, tissue oxygenation, and electroencephalogram. J Cereb Blood Flow Metab 1994; 14(1):12-19.
18. Shin HK, Dunn AK, Jones PB, et al. Vasoconstrictive neurovascular coupling during focal ischemic depolarizations. J Cereb Blood Flow Metab 2006; 26(8):1018-1030.
19. Dreier JP, Ebert N, Priller J, et al. Products of hemolysis in the subarachnoid space inducing spreading ischemia in the cortex and focal necrosis in rats: a model for delayed ischemic neurological deficits after subarachnoid hemorrhage? J Neurosurg 2000; 93(4):658-666.
20. Dreier JP, Korner K, Ebert N, et al. Nitric oxide scavenging by hemoglobin or nitric oxide synthase inhibition by N-nitro-L-arginine induces cortical spreading ischemia when K+ is increased in the subarachnoid space. J Cereb Blood Flow Metab 1998; 18(9):978-990.
21. Windmuller O, Lindauer U, Foddis M, et al. Ion changes in spreading ischemia induce rat middle cerebral artery constriction in the absence of NO. Brain 2005; 128(9):2042-2051.
22. Nedergaard M, Hansen AJ. Characterization of cortical depolarizations evoked in focal cerebral ischemia. J Cereb Blood Flow Metab 1993; 13(4):568-574.
23. Dijkhuizen RM, Beekwilder JP, van der Worp HB, et al. Correlation between tissue depolarizations and damage in focal ischemic rat brain. Brain Res 1999; 840(1-2):194-205.
24. Busch E, Gyngell ML, Eis M, et al. Potassium-induced cortical spreading depressions during focal cerebral ischemia in rats: contribution to lesion growth assessed by diffusion-weighted NMR and biochemical imaging. J Cereb Blood Flow Metab 1996; 16(6):1090-1099.
25. Takano K, Latour LL, Formato JE, et al. The role of spreading depression in focal ischemia evaluated by diffusion mapping. Ann Neurol 1996; 39(3):308-318.
26. Back T, Ginsberg MD, Dietrich WD, et al. Induction of spreading depression in the ischemic hemisphere following experimental middle cerebral artery occlusion: effect on infarct morphology. J Cereb Blood Flow Metab 1996; 16(2):202-213.
27. Gill R, Andine P, Hillered L, et al. The effect of MK-801 on cortical spreading depression in the penumbral zone following focal ischemia in the rat. J Cereb Blood Flow Metab 1992; 12(3):371-379.
28. Iijima T, Mies G, Hossmann KA. Repeated negative DC deflections in rat cortex following middle cerebral artery occlusion are abolished by MK-801: effect on volume of ischemic injury. J Cereb Blood Flow Metab 1992; 12(5):727-733.
29. Rawanduzy A, Hansen A, Hansen TW, et al. Effective reduction of infarct volume by gap junction blockade in a rodent model of stroke. J Neurosurg 1997; 87(6):916-920.
30. Hartings JA, Rolli ML, Lu XC, et al. Delayed secondary phase of peri-infarct depolarizations after focal cerebral ischemia: relation to infarct growth and neuroprotection. J Neurosci 2003; 23(37):11602-11610.
31. Strong AJ, Fabricius M, Boutelle MG, et al. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 2002; 33(12):2738-2743.
32. Sims NR, Anderson MF. Mitochondrial contributions to tissue damage in stroke. Neurochem Int 2002; 40(6):511-526.
33. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001; 21(1):2-14.
34. Siesjo BK. Acidosis and ischemic brain damage. Neurochem Pathol 1988; 9:31-88.
35. Myers RE, Yamagutchi M. Nervous system effects of cardiac arrest in monkeys. Arch Neurol 1977; 34:65-74.
36. Pulsinelli WA, Waldman S, Rawlinson D, et al. Moderate hyperglycemia augments ischemic brain damage: a neuropathologic study in the rat. Neurology 1982; 32(11):1239-1246.
37. Jorgensen HS, Nakayama H, Raaschou HO, et al. Effect of blood pressure and diabetes on stroke in progression. Lancet 1994; 344 (8916):156-159.
38. Weir CJ, Murray GD, Dyker AG, et al. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ 1997; 314(7090):1303-1306.
39. Bruno A, Biller J, Adams HP Jr. et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 1999; 52(2):280-284.
40. Bruno A, Levine SR, Frankel MR, et al. NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002; 59(5):669-674.
41. Baird TA, Parsons MW, Phanh T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 2003; 34(9):2208-2214.
42. Tracey F, Stout RW. Hyperglycemia in the acute phase of stroke and stress response. Stroke 1994; 25(2):524-525.
43. Counsell C, McDowall M, Dennis M. Hyperglycaemia after acute stroke. Other models find that hyperglycaemia is not independent predictor. BMJ 1997; 315(7111):810.
44. Schurr A. Glucose and the ischemic brain: a sour grape or a sweet treat? Curr Opin Clin Nutr Metab Care 2001; 4(4):287-292.
45. Smith-Swintosky VL, Pettigrew LC, Sapolsky RM, et al. Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures. J Cereb Blood Flow Metab 1996; 16(4):585-598.
46. Tian GF, Baker AJ. Protective effect of high glucose against ischemia-induced synaptic transmission damage in rat hippocampal slices. J Neurophysiol 2002; 88(1):236-248.
47. Seo SY, Kim EY, Kim H, et al. Neuroprotective effect of high glucose against NMDA, free radical, and oxygen-glucose deprivation through enhanced mitochondrial potentials. J Neurosci 1999; 19(20):8849-8855.
48. Ginsberg MD, Prado R, Dietrich WD, et al. Hyperglycemia reduces the extent of cerebral infarction in rats. Stroke 1987; 18(3):570-574.
49. Zasslow MA, Pearl RG, Shuer LM, et al. Hyperglycemia decreases acute neuronal ischemic changes after middle cerebral artery occlusion in cats. Stroke 1989; 20(4):519-523.
50. Parsons MW, Barber PA, Desmond PM, et al. Acute hyperglycemia adversely affects stroke outcome:a magnetic resonance imaging and spectroscopy study. Ann Neurol 2002; 52(1):20-28.
51. Winquist RJ, Kerr S. Cererbal ischemia-reperfusion injury and adhesion. Neurology 1997; 49(S4):S23-S26.
52. Emsley HC, Tyrrell PJ. Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab 2002; 22(12):1399-1419.
53. Becker KJ. Targeting the central nervous system inflammatory response in ischemic stroke. Curr Opin Neurol 2001; 14(3):349-353.
54. del Zoppo G, Ginis I, Hallenbeck JM, et al. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 2000; 10(1):95-112.
55. Zhang RL, Chopp M, Zaloga C, et al. The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat. Brain Res 1995; 682(1-2):182-188.
56. Fiszer U, Korczak-Kowalska G, Palasik W, et al. Increased expression of adhesion molecule CD1 (LFA-1beta) on the leukocytes of peripheral blood in patients with acute ischemic stroke. Acta Neurol Scand 1998; 97(4):221-224.
57. Zhang L, Zhang ZG, Zhang RL, et al. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke 2003; 34(7):1790-1795.
58. Bitsch A, Klene W, Murtada L, et al. A longitudinal prospective study of soluble adhesion molecule in acute stroke. Stroke 1998; 29(10):2129-2135.
59. Zhang RL, Chopp M, Zaloga C, et al. The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat. Brain Res 1995; 682(1-2):182-188.
60. Sanchez-Moreno C, Dashe JF, Scott T, et al. Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke 2004; 35(1):163-166.
61. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992; 23:1367-1379.
62. Matsuo Y, Onodera H, Shiga Y, et al. Role of cell adhesion molecules in brain injury after middle cerebral artery occlusion in the rat. Brain Res 1994; 656(2):344-352.
63. Hartl R, Schurer L, Schmid-Schonbein GW, et al. Experimental antileukocyte interventions in cerebral ischemia. J of Cereb Blood Flow Metab 1996; 16(6):1108-1119.
64. del Zoppo GJ, Schmid-Schonbein GW, Mori E, et al. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991; 22(10):1276-1283.
65. Mori E, del Zoppo GJ, Chambers JD. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke 1992; 23(5):712-718.
66. Chen H, Chopp M, Zhang RL, et al. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol 1994; 35:458-463.
67. Zhang RL, Chopp M, Jiang N, et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke 1995; 26(8):1438-1442.
68. Soriano SG, Coxon A, Wang YF, et al. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke 1999; 30(1):134-139.
69. Prestigiacomo CJ, Kim SC, Connolly ES Jr. Cd18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. Stroke 1999; 30(5):1110-1117.
70. Soriano SG, Lipton SA, Wang YF, et al. Intercellular adhesion molecule-1-deficient mice are less susceptible to cerebral ischemia-reperfusion injury. Ann Neurol 1996; 39(5):618-624.
71. Mocco J, Choudhri T, Huan J, et al. HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascularprotective strategy in a blinded placebo-controlled trial of non-human primate stroke. Circ Res 2002; 91(10):907-914.
72. Becker K, Kindrick D, Relton J, et al. Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke 2001; 32(1):206-211.
73. Jian N, Chopp M, Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res 1998; 788(1-2):25-34.
74. Furuya K, Takeda H, Azhar S, et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke 2001; 32(11):2665-2674.
75. Becker KJ. Anti-Leukocyte antibodies: Leukarrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke. Curr Med Res Opin 2002; 18:S18-S22.
76. Korematsu K, Goto S, Nagahiro S, et al. Microglial response to transient focal cerebral ischemia: an immunocytochemical study on the rat cerebral cortex using anti-phosphotyrosine antibody. J Cereb Blood Flow Metab 1994; 14(5):825-830.
77. Ueyama T, Ren Y, Sakai N, et al. Generation of a constitutively active fragment of PKN in microglia/macrophages after middle cerebral artery occlusion in rats. J Neurochem 2001; 79(4):903-913.
78. Marks L, Carswell HV, Peters EE, et al. Characterization of the microglial response to cerebral ischemia in the stroke-prone spontaneously hypertensive rat. Hypertension 2001; 38(1):116-122.
79. Tarozzo G, Campanella M, Ghiani M, et al. Expression of fractalkine and its receptor, CX3CR1, in response to ischemia-reperfusion brain injury in the rat. Eur J Neurosci 2002; 15(10):1663-1668.
80. Yrjänheikki J, Tikka T, Keinanen R, et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 1999; 96(23):13496-13500.
81. Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: intrinsic immuneffector cell of the brain. Brain Res Rev 1995; 20(3):269-287.
82. Gourmala NG, Buttini M, Limonta S, et al. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. J Neuroimmunol 1997; 74(1-2):35-44.
83. Priller J, Flugel A, Wehner T. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med 2001; 7(12):1356-1361.
84. Eglitis MA, Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci U S A 1997; 94(8):4080-4085.
85. Eglitis MA, Dawson D, Park KW, et al. Targeting of marrow-derived astrocytes to the ischemic brain. Neuroreport 1999; 10(6):1289-1292.
86. Wehner T, Bontert M, Eyupoglu I. Bone marrow-derived cells expressing green fluorescent protein under the control of the glial fibrillary acidic protein promoter do not differentiate into astrocytes in vitro and in vivo. J Neurosci 2003; 23(12):5004-5011.
87. Letterio JJ. Murine models define the role of TGF-beta as a master regulator of immune cell function. Cytokine Growth Factor Rev 2000; 11(1-2):81-87.
88. Ruscher K, Freyer D, Karsch M. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002; 22(23):10291-10301.
89. Trendelenburg G, Prass K, Priller J, et al. Serial analysis of gene expression identifies metallothionein-II as major neuroprotective gene in mouse focal cerebral ischemia. J Neurosci 2002; 22(14):5879-5888.
90. Davies CA, Loddick SA, Toulmond S, et al. The progression and topographic distribution of interleukin-1beta expression after permanent middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1999; 19(1):87-98.
91. Gregersen R, Lambertsen K, Finsen B. Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 2000; 20(1):53-65.
92. Stoll G. Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischemia. Rev Neurol (Paris) 2002; 158(10 Pt 1):887-891.
93. O’Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997; 20(6):252-258.
94. Iadecola C, Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol 2001; 14(1):89-94.
95. Block F, Peters M, Nolden-Koch M. Expression of IL-6 in the ischemic penumbra. Neuroreport 2000; 11(5):963-967.
96. Tarkowski E, Rosengren L, Blomstrand C, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995; 26(8):1393-1398.
97. Nawashiro H, Tasaki K, Ruetzler CA. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 1997; 17(5):483-490.
98. Bruce AJ, Boling W, Kindy MS, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996; 2(7):788-794.
99. Fontaine V, Mohand-Said S, Hanoteau N. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor J Neurosci 2002; 22(7):RC216.
100. Clark WM, Rinker LG, Lessov NS, et al. Lack of interleukin-6 expression is not protective against focal central nervous system ischemia. Stroke 2000; 31(7):1715-1720.
101. Priller J, Dirnagl U. Inflammation in stroke--a potential target for neuroprotection? Ernst Schering Res Found Workshop 2002; 39:133-157.
102. Bogdan C, Paik J, Vodovotz Y, et al. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-J Biol Chem 1992; 267(32): 23301-23308
103. Strle K, Zhou JH, Shen WH, et al. Interleukin-10 in the brain. Crit Rev Immunol 2001; 21(5):427-449.
104. Prehn JH, Backhauss C, Krieglstein J. Transforming growth factor-beta 1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo. J Cereb Blood Flow Metab 1993; 13(3):521-525.
105. Spera PA, Ellison JA, Feuerstein GZ, et al. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 1998; 251(3):189-192.
106. Becker KJ, McCarron RM, Ruetzler C, et al. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U. S. A. 1997; 94(20):10873-10878.
107. Becker K, Kindrick D, McCarron R, et al. Adoptive transfer of myelin basic protein-tolerized splenocytes to naive animals reduces infarct size: a role for lymphocytes in ischemic brain injury? Stroke 2003; 34(7):1809-1815.
108. Takeda H, Spatz M, Ruetzler C, et al. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke 2002; 33(9):2156.
109. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain damage. Trends Neurosci 1997; 20(3):132-138.
110. Crow JP, Beckman JS. The role of peroxynitrite in nitric oxide-mediated toxicity. Curr Top Microbiol Immunol 1995; 196:57-73.
111. Kolb JP. Mechanisms involved in the pro-and anti-apoptotic role of NO in human leukemia. Leukemia 2000; 14(9):1685-1694.
112. Iadecola C, Zhang F, Casey R, et al. Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke 1996; 27(8):1373-1380.
113. Forster C, Clark HB, Ross ME. Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neurpathol 1999; 97(3):215-220.
114. Iadecola C, Zhang F, Casey R, et al. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997; 17(23):9157-9164.
115. Zhang F, Casey RM, Ross ME, et al. Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke 1996; 27(2):317-323.
116. Iadecola C, Zhang, Xu X, et al. Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol 1995; 268(1 Pt 2):R286-R292.
117. Zhao X, Haensel C, Araki E. Gene-doing effect ad persistence of reduction in ischemic brian injury in mice lacking inducible nitric oxide snythase. Brain Res 2000; 872(1-2):215-218.
118. Ôbanion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999; 13(1):45-82.
119. Sairanen T, Ristimaki A, Karjalainen-Lindsberg ML, et al. Cyclooxygenase-2 is induced globally in infarcted human brain. Ann Neurol 1998; 43(6):738-747.
120. Iadecola C, Niwa K, Nogawa S, et al. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A 2001; 98(3):1294-1249.
121. Sugimoto K, Iadecola C. Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia. Brain Res 2003; 960(1-2):273-276.
122. Nagamaya M, Niwa K, Nagamaya T. The cyclooxygenase-2 inhibitor NS-398 ameliorates cerebral ischemic injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999; 19(11):1213-1219.
123. Heo JH, Lucero J, Abuiya T. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19(6):624-633.
124. Harkness KA, Adamson P, Sussman JD. Dexamethasone regulation of matrix metalloptroteinase expression in CNS vascular endothelium. Brain 2000; 123(Pt 4):698-709.
125. Fujimara M, Gasche Y, Morita-Fujimara Y. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999; 842(1):92-100.
126. Gasche Y, Fujimura M, Morita-Fujimura Y. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999; 19(9):1020-1028.
127. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000; 31(12):3034-3040.
128. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase 9 gene knockout on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21(19):7724-7732.
129. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998; 29(10):2189-2195.
130. Nagai N, Yamamoto S, Tsuboi T, et al. Tissue type plasminogen activator is involved in the process of neuronal death by oxygen-glucose deprivation. J Cereb Blood Flow Metab 2001; 21(6):631-634.
131. Wang YF, Tsirka SE, Strickland S, et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 4(2):228-231.
132. Tabrizi P, Wang L, Seeds N, et al. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol 1999; 19(11):2801-2806.
133. Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9(10):1313-1317.
134. Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs 2002; 11:1623-1632.
135. Dijkhuizen RM, Asahi M, Wu O, et al. Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model. Stroke 2002; 33(8):2100-2104.
136. Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003; 34(8):2025-2030.
137. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7(1):59-64.
138. Matys T, Strickland S. Tissue plasminogen activator and NMDA receptor cleavage. Nat Med 2003; 9(4):371-372.
139. Liberatore GT, Samson A, Bladin C, et al. Vampire bat salivary plasminogen activator (desmoteplase):a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34(2):537-543.
140. Reddrop C, Moldrich RX, Beart PM. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005; 36(6):1241-1246.
141. Hacke W, Albers G, Al-Rawi Y, et al. DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36(1):66-73.
142. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003; 348(14):1365-1375.
143. Endres M, Dirnagl U. Ischemia and stroke. Adv Exp Med Biol 2002; 513:455-473.
144. Ferrer I, Planas AM. Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. J Neuropathol Exp Neurol 2003; 62(4):329-339.
145. Mattson MP, Duan W, Pedersen WA, et al. Neurodegenerative disorders and ischemic brain diseases. Apoptosis 2001; 6(1-2):69-81.
146. Katchanov J, Waeber C, Gertz K, et al. Selective neuronal vulnerability following mild focal brain ischemia in the mouse. Brain Pathol 2003; 13(4):452-464.
147. Soriano MA, Ferrer I, Rodriguez-Farre E, et al. Apoptosis and c-Jun in the thalamus of the rat following cortical infarction. Neuroreport 1996; 7(2):425-428.
148. Le DA, Wu Y, Huang Z, et al. Caspase activation and neuroprotection in caspase-3-deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc Natl Acad Sci USA 2002; 99(23):15188-15193.
149. Hara H, Friedlander RM, Gagliardini V, et al. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 1997; 94(5):2007-2012.
150. Yu SW, Wang H, Poitras MF, et al. Mediation of poly (ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002; 297(5579):259-263.
151. Ferrer I, Friguls B, Dalfo E, et al. Caspase-dependent and caspase-independent signaling of apoptosis in the penumbra following middle cerebral artery occlusion in the adult rat. Neuropathol Appl Neurobiol 2003; 29(5):472-481.
152. Endres M, Wang ZQ, Namura S, et al. Ischemic brain injury is mediated by the activation of poly(ADP-ribose) polymerase. J Cereb Blood Flow Metab 1997; 17(11):1143-1151.
153. Eliasson MJ, Sampei K, Mandir AS, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 1997; 3(10):1089-1095.
154. Ying W, Garnier P, Swanson RA. NAD+ repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. Biochem Biophys Res Commun 2003; 308(4):809-813.
155. Love S. Apoptosis and brain ischemia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(2):267-282.
156. Mattson MP, Liu D. Mitochondrial potassium channels and uncoupling proteins in synaptic plasticity and neuronal cell death. Biochem Biophys Res Commun 2003; 304(3):539-549.
157. van Gurp M, Festjens N, van Loo G, et al. Mitochondrial intermembrane proteins in cell death. Biochem Biophys Res Commun 2003; 304(3):487-497.
158. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome C and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91(4):479-489.
159. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407(6805):770-776.
160. Linnik MD, Zahos P, Geschwind MD, et al. Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke 1995; 26(9):1670-1674.
161. Martinou JC, Dubois-Dauphin M, Staple JK, et al. Overexpression of bcl-2 in transgenic mice protects neurons from naturally occuring cell death and experimental ischemia. Neuron 1994;13:1017-1030.
162. Wiessner C, Allegrini PR, Rupalla K, et al. Neuron-specific transgene expression of Bcl-XL but not Bcl-2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice. Neurosci Lett 1999; 268(3):119-222.
163. Cao G, Pei W, Ge H, et al. Vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 2002; 22(13):5423-5431.
164. Kilic E, Dietz GP, Hermann DM, et al. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann Neurol 2002; 52(5):617-622.
165. Trapp T, Korhonen L, Besselmann M, et al. Transgenic mice overexpressing XIAP in neurons show better outcome after transient cerebral ischemia. Mol Cell Neurosci 2003; 23(2):302-313.
166. Saito A, Hayashi T, Okuno S, et al. Interaction between XIAP and Smac/DIABLO in the mouse brain after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2003; 23(9):1010-1019.
167. Lindahl T. Instability and decay of the primary structure of DNA. Nature 1993; 362(6422):709-715.
168. Jaruga P, Dizdaroglu M. Repair of products of oxidative DNA base damage in human cells. Nucleic Acids Res 1996; 24(8):1389-1394.
169. Liu PK, Grossman RG, Hsu CY, Robertson CS. Ischemic injury and faulty gene transcripts in the brain. Trends Neurosci 2001; 24(10):581-588.
170. Liu PK, Hsu CY, Dizdaroglu M, et al. Damage, repair, and mutagensis in nuclear genes after mouse forebrain ischemia-reperfusion. J Neurosci 1996; 16(21):6795-6806.
171. Englander EW, Hu Z, Sharma A. Rat MYH, a glycosylase for repair of oxidatively damaged DNA, has brain-specific isoforms that localize to neuronal mitochondria. J Neurochem 2002; 83(6):1471-1480.
172. Chopp M, Chan PH, Hsu CY, et al. DNA damage and repair in central nervous system injury:national institute of neurological disorders and stroke workshop summary. Stroke 1996; 27(3):363-369.
173. Lan J, Li W, Zhang F, et al. Inducible repair of oxidative DNA lesions in the rat brain after transient focal ischemia and reperfusion. J Cereb Blood Flow Metab 2003; 23(11):1324-1339.
174. Endres M, Biniszkiewicz D, Sobol RW, et al. Increased postischemic brain injury in mice deficient in uracil-DNA glycosylase. J Clin Invest 2004; 113(12):1711-1721.
175. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10(4):431-442.
176. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature 1996; 381(6584):643-644.
177. Chopp M, Li Y, Zhang ZG, et al. p53 expression in brain after middle cerebral artery occlusion in the rat. Biochem Biophys Res Commun 1992; 182(3):1201-1207.
178. Li Y, Chopp M, Zhang ZG, et al. p53-immunoreactive protein and p53 mRNA expression after transient middle cerebral artery occlusion in rats. Stroke 1994; 25(4):849-855.
179. Crumrine RC, Thomas AL, Morgan PF. Attenuation of p53 expression protects against focal ischemic damage in transgenic mice. J Cereb Blood Flow Metab 1994; 14(6):887-891.
180. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 2003; 26:248-254.
181. Weih M, Prass K, Ruscher K, et al. Ischemia tolerance; model for research, hope for clinical practice? Nervenarzt 2001; 72:255-260.
182. Kirino T. Ischemic tolerance. J Cereb Blood Flow Metab 2002; 22(11):1283-1296.
183. Weih M, Kallenberg K, Bergk A, et al. Attenuated stroke severity after prodromal TIA: a role for ischemic tolerance in the brain? Stroke 1999; 30(9):1851-1854.
184. Wegener S, Gottschalk B, Jovanovic V, et al. MRI in Acute Stroke Study Group of the German Competence Network Stroke. Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke 2004; 35:616-621.
185. Ruscher K, Isaev N, Trendelenburg G, et al.. Induction of hypoxia inducible factor 1 by oxygen glucose deprivation is attenuated by hypoxic preconditioning in rat cultured neurons. Neurosci Lett 1998; 254(2):117-120.
186. Prass K, Ruscher K, Karsch M, et al. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blood Flow Metab 2002; 22(5):520-525.
187. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6(6):484-494.
188. Prass K, Scharff A, Ruscher K, et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 2003; 34(8):1981-1986.
189. Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 2004; 5(6):437-448.
190. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97(19):10526-10531.
191. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95(8):4635-4640.
192. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8(8):495-505.
193. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Scienc. 2004; 305(5681):239-242.